Join

Compare · ACHV vs NNNN

ACHV vs NNNN

Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACHV and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • NNNN is the larger of the two at $3.31B, about 6.3x ACHV ($526.6M).
  • ACHV has been more active in the news (10 items in the past 4 weeks vs 1 for NNNN).
  • ACHV has more recent analyst coverage (8 ratings vs 0 for NNNN).
MetricACHVNNNN
Company
Achieve Life Sciences Inc.
Anbio Biotechnology
Price
-
-
Market cap
$526.6M
$3.31B
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2025
News (4w)
10
1
Recent ratings
8
0
ACHV

Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Latest ACHV

Latest NNNN